NorthStar Medical Radioisotopes Enters U.S. Supply Agreement for Commercial Supply of Therapeutic Radioisotope Copper-67 (Cu-67) Exclusively to Clarity Pharmaceuticals for Its Targeted Copper Theranostics Programs
Retrieved on:
Tuesday, May 25, 2021
Research, Medical devices, Biotechnology, Radiology, Health, Pharmaceutical, Other Science, Science, Oncology, Chemistry, Physical sciences, Natural sciences, Chelation, Coordination chemistry, Equilibrium chemistry, Copper, Northstar, Radiopharmacology, Clarity Pharmaceuticals (Clarity), NorthStar Medical Radioisotopes, LLC (NorthStar), CLARITY PHARMACEUTICALS (CLARITY), NORTHSTAR MEDICAL RADIOISOTOPES, LLC (NORTHSTAR)
Under the agreement, NorthStar will supply Cu-67 exclusively to Clarity Pharmaceuticals as an active pharmaceutical ingredient used to support Claritys Targeted Copper Theranostics (TCT) programs.
Key Points:
- Under the agreement, NorthStar will supply Cu-67 exclusively to Clarity Pharmaceuticals as an active pharmaceutical ingredient used to support Claritys Targeted Copper Theranostics (TCT) programs.
- Previously, the lack of an effective copper chelating technology has limited the clinical development of Cu-67 products and subsequent commercial production of Cu-67, said Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes.
- NorthStar is addressing the need for reliable Cu-67 radioisotope supply by advancing towards commercial-scale production.
- Clarity leads the world in the development and commercialization of TCT, said Alan Taylor, PhD, Executive Chairman of Clarity Pharmaceuticals.